Ohsu Knight Cancer Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Provider Training in Increasing Patient Tobacco Cessation Counseling and Referrals for Patients With Cancer Undergoing Radiation Therapy
Not Applicable
Completed
- Conditions
- Lung CarcinomaProstate CarcinomaCaregiverHead and Neck CarcinomaBreast CarcinomaTobacco Use
- Interventions
- Other: Communication Skills TrainingOther: Medical Chart ReviewOther: Questionnaire AdministrationOther: Tobacco Cessation Counseling
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03135782
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant
Phase 2
Completed
- Conditions
- Malignant Neoplasm
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 43
- Registration Number
- NCT03097588
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Exercise and Nutrition Program in Improving Physical Activity and Dietary Behavior in Non-Active, Overweight, or Obese Latinas
Not Applicable
Completed
- Conditions
- ObesityOverweight
- Interventions
- Behavioral: Exercise InterventionBehavioral: Nutritional Intervention
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT03028935
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
Phase 1
Completed
- Conditions
- Locally Advanced AngiosarcomaLocally Advanced LeiomyosarcomaLocally Advanced Malignant Peripheral Nerve Sheath TumorMetastatic Epithelioid SarcomaMetastatic FibrosarcomaMetastatic Undifferentiated Pleomorphic SarcomaUnresectable LeiomyosarcomaLocally Advanced MyxofibrosarcomaMetastatic AngiosarcomaMyxofibrosarcoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT03009201
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Assessing Community Cancer Care After Insurance ExpanSionS
Completed
- Conditions
- Cancer
- Interventions
- Other: Medicaid Expansion
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 1939783
- Registration Number
- NCT02936609
Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease
Not Applicable
Completed
- Conditions
- Esophageal AdenocarcinomaBarrett EsophagusEsophageal Squamous Cell CarcinomaGastroesophageal Reflux DiseaseDysplasiaMetaplasia
- Interventions
- Other: Cytology Specimen Collection ProcedureOther: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentDevice: Swallowable Sponge Cell Sampling Device
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT02890979
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Computer-Based Behavior Change Guide in Increasing Physical Activity in Patients With Prostate Cancer Who Have Received Androgen Deprivation Therapy
Not Applicable
Completed
- Conditions
- Prostate Carcinoma
- Interventions
- Other: Computer-Assisted InterventionOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 56
- Registration Number
- NCT02869412
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer
Early Phase 1
Withdrawn
- Conditions
- Stage IIIA Esophageal Cancer AJCC v7Stage IIB Esophageal Cancer AJCC v7Stage III Esophageal Cancer AJCC v7Stage IIIB Esophageal Cancer AJCC v7Stage IIIC Esophageal Cancer AJCC v7
- Interventions
- Procedure: Magnetic Resonance Imaging
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT02857218
Pre-Prostatectomy Celecoxib or Placebo
Phase 2
Terminated
- Conditions
- Adenocarcinoma of the ProstateProstate Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT02840162
- Locations
- 🇺🇸
Portland VA Medical Center, Portland, Oregon, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
Phase 1
Completed
- Conditions
- Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia
- Interventions
- Device: In Vitro Kinase Inhibitor AssayBiological: Rituximab
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT02779283
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
© Copyright 2025. All Rights Reserved by MedPath